This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ERYP vs. PLX, IKT, IZTC, JATT, CRTX, ZIVO, ALVR, FNCH, SRNE, and SQZShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), JATT Acquisition (JATT), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AlloVir (ALVR), Finch Therapeutics Group (FNCH), Sorrento Therapeutics (SRNE), and SQZ Biotechnologies (SQZ). These companies are all part of the "medical" sector. ERYTECH Pharma vs. Its Competitors Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies JATT Acquisition Cortexyme ZIVO Bioscience AlloVir Finch Therapeutics Group Sorrento Therapeutics SQZ Biotechnologies Protalix BioTherapeutics (NYSE:PLX) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability. Does the media refer more to PLX or ERYP? In the previous week, Protalix BioTherapeutics' average media sentiment score of 0.00 equaled ERYTECH Pharma'saverage media sentiment score. Company Overall Sentiment Protalix BioTherapeutics Neutral ERYTECH Pharma Neutral Which has preferable earnings and valuation, PLX or ERYP? Protalix BioTherapeutics has higher revenue and earnings than ERYTECH Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$61.95M3.20$8.31M$0.0735.57ERYTECH Pharma$32.66M3.24-$240KN/AN/A Which has more risk and volatility, PLX or ERYP? Protalix BioTherapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Do institutionals and insiders believe in PLX or ERYP? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 1.9% of ERYTECH Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is PLX or ERYP more profitable? ERYTECH Pharma has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. ERYTECH Pharma's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% ERYTECH Pharma N/A N/A N/A Do analysts recommend PLX or ERYP? Protalix BioTherapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 502.41%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryProtalix BioTherapeutics beats ERYTECH Pharma on 7 of the 12 factors compared between the two stocks. Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$357.40M$6.04B$10.49BDividend YieldN/AN/A5.73%4.80%P/E RatioN/AN/A85.1927.32Price / Sales3.24500.97516.16194.55Price / CashN/A22.4437.5761.53Price / Book3.883.8812.426.81Net Income-$240K-$133.30M$3.32B$276.59M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049PLXProtalix BioTherapeutics1.8964 of 5 stars$2.57+2.8%$15.00+483.7%+123.6%$204.91M$61.95M-19.77200Gap UpIKTInhibikase Therapeutics1.2838 of 5 stars$1.66+2.5%$6.50+291.6%+1.9%$123.70MN/A-0.626IZTCInvizyne TechnologiesN/A$13.50flatN/AN/A$84.40MN/A0.0029JATTJATT AcquisitionN/A$4.17+6.1%N/A-52.7%$71.93MN/A0.003Gap DownHigh Trading VolumeCRTXCortexymeN/A$1.78-8.7%N/A+169.5%$53.67MN/A-0.6055High Trading VolumeZIVOZIVO Bioscience0.111 of 5 stars$12.00+2.1%N/A-34.6%$45.80M$15.85K-2.4610Gap UpALVRAlloVirN/A$7.72-3.9%N/A-75.8%$38.93MN/A-0.38110High Trading VolumeFNCHFinch Therapeutics GroupN/A$12.10+0.6%N/A+3.9%$19.43MN/A-1.37190SRNESorrento Therapeutics0.8865 of 5 stars$0.00+12.5%N/A+66.7%$2.48M$60.32M0.00800Gap UpSQZSQZ BiotechnologiesN/A$0.03flatN/A+21.7%$826K$18.16M-0.011,620 Related Companies and Tools Related Companies PLX Alternatives IKT Alternatives IZTC Alternatives JATT Alternatives CRTX Alternatives ZIVO Alternatives ALVR Alternatives FNCH Alternatives SRNE Alternatives SQZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERYP) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
